Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  47 results for ""BNT162 Vaccine""

Your Filters

Publisher : wiley-liss Subject : antibody formation Subject : covid-19 Subject : emotional engagement Subject : neoplasms
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Editorial & Opinion

Letter to the Editor: The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer.

  • Authors : Uygur A; Department of Public Health, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.; Sayılı U

Subjects: BNT162 Vaccine* ; Neoplasms*/Neoplasms*/Neoplasms*/therapy; Humans

  • Source: Journal of medical virology [J Med Virol] 2023 Mar; Vol. 95 (3), pp. e28664.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients.

  • Authors : Zaleska J; Department of Experimental Hematooncology, Medical University of Lublin, Lublin, Poland.; Department of Hematology, St John's Cancer Centre, Lublin, Poland.

Subjects: BNT162 Vaccine*/BNT162 Vaccine*/BNT162 Vaccine*/immunology ; COVID-19*/COVID-19*/COVID-19*/prevention & control ; Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/Leukemia, Lymphocytic, Chronic, B-Cell*/immunology

  • Source: International journal of cancer [Int J Cancer] 2023 Feb 15; Vol. 152 (4), pp. 705-712. Date of Electronic Publication: 2022 Jul 27.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy.

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; Neoplasms*/Neoplasms*/Neoplasms*/therapy; Humans

  • Source: International journal of cancer [Int J Cancer] 2023 Feb 15; Vol. 152 (4), pp. 679-685. Date of Electronic Publication: 2022 Sep 23.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection.

  • Authors : La Verde N; Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy.; Riva A

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; Neoplasms*/Neoplasms*/Neoplasms*/therapy; Humans

  • Source: International journal of cancer [Int J Cancer] 2023 Feb 15; Vol. 152 (4), pp. 661-671. Date of Electronic Publication: 2022 Sep 28.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey.

  • Authors : Çağlayan D; Department of Public Health, Division of Epidemiology, School of Medicine, Dokuz Eylül University, Izmir, Turkey.; Süner AF

Subjects: BNT162 Vaccine* ; COVID-19*/COVID-19*/COVID-19*/prevention & control; Antibodies, Viral

  • Source: Journal of medical virology [J Med Virol] 2022 May; Vol. 94 (5), pp. 2212-2221. Date of Electronic Publication: 2022 Feb 03.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Antibody response 6 months after the booster dose of Pfizer in previous recipients of CoronaVac.

Subjects: Antibody Formation* ; COVID-19*/COVID-19*/COVID-19*/prevention & control; Humans

  • Source: Journal of medical virology [J Med Virol] 2023 Jan; Vol. 95 (1), pp. e28169. Date of Electronic Publication: 2022 Oct 01.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Unremarkable antibody responses against various infectious agents after inoculation with the BNT162b2 COVID-19 vaccine.

  • Authors : Kozawa K; Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.; Miura H

Subjects: Antibody Formation* ; COVID-19*/COVID-19*/COVID-19*/prevention & control; Antibodies, Viral

  • Source: Journal of medical virology [J Med Virol] 2022 Oct; Vol. 94 (10), pp. 4583-4585. Date of Electronic Publication: 2022 Jun 09.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer.

  • Authors : Simsek M; Departments of Medical Oncology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.; Yasin AI

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; Neoplasms*/Neoplasms*/Neoplasms*/complications ; Vaccines*

  • Source: Journal of medical virology [J Med Virol] 2022 Sep; Vol. 94 (9), pp. 4138-4143. Date of Electronic Publication: 2022 May 14.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine.

  • Authors : Woo W; Department of Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.; Kim AY

Subjects: 2019-nCoV Vaccine mRNA-1273/2019-nCoV Vaccine mRNA-1273/2019-nCoV Vaccine mRNA-1273/*adverse effects ; BNT162 Vaccine/BNT162 Vaccine/BNT162 Vaccine/*adverse effects ; COVID-19/COVID-19/COVID-19/*prevention & control

  • Source: Journal of medical virology [J Med Virol] 2022 Apr; Vol. 94 (4), pp. 1566-1580. Date of Electronic Publication: 2021 Dec 14.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2.

  • Authors : Almanzar G; Department of Pediatrics, Pediatric Rheumatology/Special Immunology, University Hospital Würzburg, Würzburg, Germany.; Koosha K

Subjects: COVID-19*/COVID-19*/COVID-19*/immunology ; COVID-19*/COVID-19*/COVID-19*/prevention & control ; Antibodies, Viral*/Antibodies, Viral*/Antibodies, Viral*/blood COVID-19 breakthrough infections

  • Source: Journal of medical virology [J Med Virol] 2024 Jun; Vol. 96 (6), pp. e29739.Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print Cited Medium:

Record details

Read More Add to Saved list
×
  • 1-10 of  47 results for ""BNT162 Vaccine""